checkAd
    Startseite > Aktien > Enveric Biosciences > Nachrichten
    Enveric Biosciences Aktie
    0,8350
     
    USD
    +2,45 %
    +0,0200 USD
    Letzter Kurs 02:00:00 NYSE
    0,8005
     
    USD
    200 STK
    Geldkurs 22.05.24
    0,9006
     
    USD
    100 STK
    Briefkurs 22.05.24
    ISIN: US29405E2081 · WKN: A3DMHB · SYM: ENVB · USA

    Neueste Nachrichten

    Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
    15.05.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
    14.05.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
    08.05.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
    26.03.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
    19.03.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
    12.03.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
    29.02.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
    23.02.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
    21.02.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
    03.01.24 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
    29.12.23 · Business Wire (engl.) · Enveric Biosciences
    Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
    28.12.23 · Business Wire (engl.) · Enveric Biosciences